Skip to content

In the BioHarmony Drug Report Database


Minipress, Minipress Xl (prazosin) is a small molecule pharmaceutical. Prazosin was first approved as Minipress on 1982-01-01. It is used to treat hypertension, prostatic hyperplasia, raynaud disease, and urinary retention in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1B adrenergic receptor, and alpha-1D adrenergic receptor. In addition, it is known to target alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, alpha-2C adrenergic receptor, and ribosyldihydronicotinamide dehydrogenase [quinone].
Trade Name Minipress, Minipress Xl
Common Name Prazosin
Indication hypertension, prostatic hyperplasia, raynaud disease, urinary retention
Drug Class Antihypertensives (prazosin type)
Get full access now